Alterations of TP53 are associated with a poor outcome for patients with hepatocellular carcinoma: Evidence from a systematic review and meta-analysis

European Journal of Cancer

Volumn 48, Issue 15, 2012, Pages 2328-2338

  Liu, Jiangbo ^a   Ma, Qingyong ^a   Zhang, Min ^a   Wang, Xinshuai ^b   Zhang, Dong ^a   Li, Wei ^a   Wang, Fengfei ^c   Wu, Erxi ^c  

^a MEDICAL SCHOOL OF XI AN JIAOTONG UNIVERSITY   (China)

^b HENAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c NORTH DAKOTA STATE UNIVERSITY   (United States)

Author keywords

Hepatocellular carcinoma; Meta analysis; Systematic review; TP53; Tumour marker

Indexed keywords

ANTI P53 ANTIBODY; ANTIBODY; PROTEIN P53; UNCLASSIFIED DRUG;

ANTIBODY BLOOD LEVEL; CANCER PATIENT; GENE MUTATION; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; META ANALYSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEFECT; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; RECURRENCE FREE SURVIVAL; REVIEW; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW;

EID: 84866740163     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2012.03.001     Document Type: Article

References (59)

1. J. Ferlay, H.R. Shin, and F. Bray Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 Int J Cancer 127 12 2010 2893 2917
2. A. Jemal, R. Siegel, and E. Ward Cancer Statistics, 2009 CA Cancer J Clin 59 4 2009 225 249
3. K.A. McGlynn, L. Tsao, A.W. Hsing, S.S. Devesa, and J.F. Fraumeni Jr. International trends and patterns of primary liver cancer Int J Cancer 94 2 2001 290 296
4. C. La Vecchia, F. Lucchini, S. Franceschi, E. Negri, and F. Levi Trends in mortality from primary liver cancer in Europe Eur J Cancer 36 7 2000 909 915
5. P. Tandon, and G. Garcia-Tsao Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies Liver Int 29 4 2009 502 510
6. G. Cabibbo, M. Enea, and M. Attanasio A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma Hepatology 51 4 2010 1274 1283
7. P.B. Lai, T.Y. Chi, and G.G. Chen Different levels of p53 induced either apoptosis or cell cycle arrest in a doxycycline-regulated hepatocellular carcinoma cell line in vitro Apoptosis 12 2 2007 387 393
8. S.P. Dowell, P.O. Wilson, N.W. Derias, D.P. Lane, and P.A. Hall Clinical utility of the immunocytochemical detection of p53 protein in cytological specimens Cancer Res 54 11 1994 2914 2918
9. N.H. Park, Y.H. Chung, and K.H. Youn Close correlation of p53 mutation to microvascular invasion in hepatocellular carcinoma J Clin Gastroenterol 33 5 2001 397 401
10. B. Terris, P. Laurent-Puig, and J. Belghitti Prognostic influence of clinicopathologic features, DNA-ploidy, CD44H and p53 expression in a large series of resected hepatocellular carcinoma in France Int J Cancer 74 6 1997 614 619
11. R.H. Yuan, Y.M. Jeng, and H.L. Chen Stathmin overexpression cooperates with p53 mutation and osteopontin overexpression, and is associated with tumour progression, early recurrence, and poor prognosis in hepatocellular carcinoma J Pathol 209 4 2006 549 558
12. M.M. Atta, S.A. El-Masry, M. Abdel-Hameed, H.A. Baiomy, and N.E. Ramadan Value of serum anti-p53 antibodies as a prognostic factor in Egyptian patients with hepatocellular carcinoma Clin Biochem 41 14-15 2008 1131 1139
13. T.H. Hu, C.C. Wang, and C.C. Huang Down-regulation of tumour suppressor gene PTEN, overexpression of p53, plus high proliferating cell nuclear antigen index predict poor patient outcome of hepatocellular carcinoma after resection Oncol Rep 18 6 2007 1417 1426
14. A.W. Liu, J. Cai, and X.L. Zhao The clinicopathological significance of BUBR1 overexpression in hepatocellular carcinoma J Clin Pathol 62 11 2009 1003 1008
15. C. Stroescu, A. Dragnea, and B. Ivanov Expression of p53, Bcl-2, VEGF, Ki67 and PCNA and prognostic significance in hepatocellular carcinoma J Gastrointest Liver Dis 17 4 2008 411 417
16. G. Shiota, Y. Kishimoto, and A. Suyama Prognostic significance of serum anti-p53 antibody in patients with hepatocellular carcinoma J Hepatol 27 4 1997 661 668
17. M. Müller, M. Meyer, and T. Schilling Testing for anti-p53 antibodies increases the diagnostic sensitivity of conventional tumour markers Int J Oncol 29 4 2006 973 980
18. R. Parasole, F. Izzo, and F. Perrone Prognostic value of serum biological markers in patients with hepatocellular carcinoma Clin Cancer Res 7 11 2001 3504 3509
19. R. Saffroy, J.C. Lelong, and D. Azoulay Clinical significance of circulating anti-p53 antibodies in European patients with hepatocellular carcinoma Br J Cancer 79 3-4 1999 604 610
20. C.T. Yeh, C.J. Kuo, and M.W. Lai CD133-positive hepatocellular carcinoma in an area endemic for hepatitis B virus infection BMC Cancer 11 9 2009 324
21. M.F. Zhang, Z.Y. Zhang, J. Fu, Y.F. Yang, and J.P. Yun Correlation between expression of p53, p21/WAF1, and MDM2 proteins and their prognostic significance in primary hepatocellular carcinoma J Transl Med 7 2009 110
22. H. Hayashi, K. Sugio, and T. Matsumata The clinical significance of p53 gene mutation in hepatocellular carcinomas from Japan Hepatology 22 6 1995 1702 1707
23. H. Sugo, S. Takamori, K. Kojima, T. Beppu, and S. Futagawa The significance of p53 mutations as an indicator of the biological behavior of recurrent hepatocellular carcinomas Surg Today 29 9 1999 849 855
24. M. Yano, K. Hamatani, and H. Eguchi Prognosis in patients with hepatocellular carcinoma correlates to mutations of p53 and/or hMSH2 genes Eur J Cancer 43 6 2007 1092 1100
25. C.D. Mann, C.P. Neal, and G. Garcea Prognostic molecular markers in hepatocellular carcinoma: a systematic review Eur J Cancer 43 6 2007 979 992
26. Wells GA, Brodsky L, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. Available from: < http://www.ohri.ca/programs/clinical/epidemiology/oxford.htm > [accessed 7 July 2010].
27. J.F. Tierney, L.A. Stewart, D. Ghersi, S. Burdett, and M.R. Sydes Practical methods for incorporating summary time-to-event data into meta-analysis Trials 8 2007 16
28. R. DerSimonian, and N. Laird Meta-analysis in clinical trials Control Clin Trials 7 3 1986 177 188
29. S.G. Thompson, and J.P.T. Higgins How should meta-regression analyses be undertaken and interpreted? Stat Med 21 11 2002 1559 1573
30. M. Egger, G. Davey Smith, M. Schneider, and C. Minder Bias in meta-analysis detected by a simple, graphical test BMJ 315 7109 1997 629 634
31. K. Honda, E. Sbisà, and A. Tullo p53 mutation is a poor prognostic indicator for survival in patients with hepatocellular carcinoma undergoing surgical tumour ablation Br J Cancer 77 5 1998 776 782
32. H. Su, J. Zhao, and Y. Xiong Large-scale analysis of the genetic and epigenetic alterations in hepatocellular carcinoma from Southeast China Mutat Res 641 1-2 2008 27 35
33. M. Anzola, A. Saiz, and N. Cuevas High levels of p53 protein expression do not correlate with p53 mutations in hepatocellular carcinoma J Viral Hepat 11 6 2004 502 510
34. C.T. Chiu, T.S. Yeh, J.C. Hsu, and M.F. Chen Expression of Bcl-2 family modulated through p53-dependent pathway in human hepatocellular carcinoma Dig Dis Sci 48 4 2003 670 676
35. K. Endo, T. Ueda, T. Ohta, and T. Terada Protein expression of MDM2 and its clinicopathological relationships in human hepatocellular carcinoma Liver 20 3 2000 209 215
36. S. Gianni, A. Cecchetto, and G. Altavilla Tumour staging, morphology and p53 overexpression concur in predicting survival in hepatocellular carcinoma J Intern Med 257 4 2005 367 373
37. R.P. Guo, C. Zhong, and M. Shi Clinical value of apoptosis and angiogenesis factors in estimating the prognosis of hepatocellular carcinoma J Cancer Res Clin Oncol 132 9 2006 547 555
38. G. Guzman, V. Alagiozian-Angelova, and J.E. Layden-Almer p53, Ki-67, and serum alpha feto-protein as predictors of hepatocellular carcinoma recurrence in liver transplant patients Modern Pathol 18 11 2005 1498 1503
39. T. Kobayashi, Y. Sugawara, Y.Z. Shi, and M. Makuuchi Telomerase expression and p53 status in hepatocellular carcinoma Am J Gastroenterol 97 12 2002 3166 3171
40. K. Mise, S. Tashiro, and S. Yogita Assessment of the biological malignancy of hepatocellular carcinoma: relationship to clinicopathological factors and prognosis Clin Cancer Res 4 6 1998 1475 1482
41. T. Naka, N. Toyota, T. Kaneko, and N. Kaibara Protein expression of p53, p21WAF1, and Rb as prognostic indicators in patients with surgically treated hepatocellular carcinoma Anticancer Res 18 1B 1998 555 564
42. S. Osada, S. Saji, and T. Kuno Clinical significance of combination study of apoptotic factors and proliferating cell nuclear antigen in estimating the prognosis of hepatocellular carcinoma J Surg Oncol 85 1 2004 48 54
43. H.X. Qin, K.J. Nan, and G. Yang Expression and clinical significance of TAp73α, p53, PCNA and apoptosis in hepatocellular carcinoma World J Gastroenterol 11 18 2005 2709 2713
44. L.X. Qin, Z.Y. Tang, and Z.C. Ma p53 immunohistochemical scoring: an independent prognostic marker for patients after hepatocellular carcinoma resection World J Gastroenterol 8 3 2002 459 463
45. M. Schöniger-Hekele, S. Hänel, F. Wrba, and C. Müller Hepatocellular carcinoma-survival and clinical characteristics in relation to various histologic molecular markers in Western patients Liver Int 25 1 2005 62 69
46. Y. Soini, N. Virkajärvi, V.P. Lehto, and P. Pääkkö Hepatocellular carcinomas with a high proliferation index and a low degree of apoptosis and necrosis are associated with a shortened survival Br J Cancer 73 9 1996 1025 1030
47. C.O. Sung, B.C. Yoo, K.C. Koh, J.W. Cho, and C.K. Park Prognostic significance of p53 overexpression after hepatic resection of hepatocellular carcinoma Korean J Gastroenterol 45 6 2005 425 430
48. A. Umemura, Y. Itoh, and K. Itoh Association of gankyrin protein expression with early clinical stages and insulin-like growth factor-binding protein 5 expression in human hepatocellular carcinoma Hepatology 47 2 2008 493 502
49. P.C. Wu, V.K. Lau, and J.W. Fang Imbalance between cell proliferation and cellular DNA fragmentation in hepatocellular carcinoma Liver 19 5 1999 444 451
50. V. Sitruk, J. Vaysse, and S. Chevret Prevalence and prognostic value of serum anti-p53 antibodies in hepatocellular carcinoma. A study of 159 patients Gastroenterol Clin Biol 24 12 2000 1159 1163
51. P. Tangkijvanich, A. Janchai, and N. Charuruks Clinical associations and prognostic significance of serum anti-p53 antibodies in Thai patients with hepatocellular carcinoma Asian Pac J Allergy Immunol 18 4 2000 237 243
52. J. Bruix, M. Sherman, and J.M. Llovet Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL Conference J Hepatol 35 3 2001 421 430
53. B. Bressac, M. Kew, J. Wands, and M. Ozturk Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa Nature 350 6317 1991 429 431
54. T. Teramoto, K. Satonaka, and S. Kitazawa p53 gene abnormalities are closely-related to hepatoviral infections and occur at a late-stage of hepatocarcinogenesis Cancer Res 54 1 1994 231 235
55. C.A. Midgley, and D.P. Lane p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding Oncogene 15 10 1997 1179 1189
56. Q. Su, C.H. Schroder, G. Otto, and P. Bannasch Overexpression of p53 protein is not directly related to hepatitis B × protein expression and is associated with neoplastic progression in hepatocellular carcinomas rather than hepatic preneoplasia Mutat Res Rev Mutat 462 2-3 2000 365 380
57. B. George, R.H. Datar, and L. Wu p53 gene and protein status: the role of p53 alterations in predicting outcome in patients with bladder cancer J Clin Oncol 25 34 2007 5352 5358
58. M. Volkmann, M. Müller, and W.J. Hofmann The humoral immune response to p53 in patients with hepatocellular carcinoma is specific for malignancy and independent of the alpha-fetoprotein status Hepatology 18 3 1993 559 565
59. L.M. McShane, D.G. Altman, and W. Sauerbrei REporting recommendations for tumor MARKer prognostic studies (REMARK) Eur J Cancer 41 12 2005 1690 1696